RxDoctor Payments Data

Zulfiqar Arif, MD

Internal Medicine · Abington, PANPI 1790030724

Payments from drug & device makers

$4,155in general payments, 2019–2025

Across 229 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$625
  • Novo Nordisk$571
  • AstraZeneca$411
  • Lilly USA, LLC$326
  • Astellas Pharma US Inc$296
  • AbbVie$241
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,155100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,155 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$156,047
Medicare patients
526
Services billed
1,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$115,353
TrulicityDulaglutide54$94,567
EliquisApixaban58$64,499
MounjaroTirzepatide26$30,734
JanuviaSitagliptin Phosphate23$28,349
JardianceEmpagliflozin15$20,851
EntrestoSacubitril/Valsartan17$18,092
XareltoRivaroxaban12$16,994
Breo ElliptaFluticasone/Vilanterol12$6,342
Atorvastatin Calcium470$6,161
Rosuvastatin Calcium215$4,087
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$3,873
SynthroidLevothyroxine Sodium31$3,686
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$3,533
Metformin Hcl170$3,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$326$125,30080 claims
Novo NordiskOzempic$571$115,35373 claims
PfizerEliquis, Paxlovid$625$65,92874 claims
MerckJanuvia$26$28,34923 claims
Boehringer IngelheimJardiance$53$20,85115 claims
GSKBreo Ellipta$117$6,34212 claims
AbbVieSynthroid$241$3,68631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →